Research and development of immunosuppressive therapies using immune tolerance induction in collaboration with Juntendo University
First written in FY2017. 4 of 7 entries say "Restated". Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019RestatedAnnual report
「In addition, for the development of a new immunosuppressive treatment using the induction of immune tolerance, which is being jointly researched with Juntendo University, in September 2017 we entered into an outsourcing and contract research agreement with MEDINET Co.,Ltd. to establish a cell-processing platform for commercializing the technology, and are working to establish a framework for the next step, clinical trials.」
The company continues to establish a framework for the practical application and clinical trials of the immunosuppressive therapy in collaboration with Juntendo University and MEDINET Co.,Ltd. - FY2019-Q2ReframedAnnual report
「Regarding the joint research and development with Juntendo University of a new immunosuppressive therapy using induced immune tolerance, the company agreed to transfer its research results to JUNTEN BIO, newly established to accelerate the research and development, and its position in future research and development changed to JUNTEN BIO.」
Regarding the joint research and development with Juntendo University, the company arranged for the research results and its position in future research and development to change to the newly established JUNTEN BIO. - FY2019-Q1RestatedAnnual report
「In September 2017, the company entered into an outsourcing agreement with MEDINET Co.,Ltd. to establish a cell-processing platform for the practical application of the technology, and is working to establish a framework for the next step, clinical trials.」
The company continues to establish a framework for clinical trials of the immunosuppressive therapy using induced immune tolerance in collaboration with Juntendo University and MEDINET Co.,Ltd. - FY2018RestatedAnnual report
「In September 2017, the company entered into an outsourcing agreement with MEDINET Co.,Ltd. to establish a cell-processing platform for the practical application of the technology, and is working to establish a framework for the next step, clinical trials.」
The company continues to establish a framework for clinical trials of the immunosuppressive therapy using induced immune tolerance in collaboration with Juntendo University and MEDINET Co.,Ltd. - FY2018-Q3RestatedAnnual report
「In addition, for the development of a new immunosuppressive therapy using induced immune tolerance in collaboration with Juntendo University, the company entered into an outsourcing agreement with MEDINET Co.,Ltd. in September 2017 to establish a cell-processing platform for the practical application of the technology, and is working to establish a framework for the next step, clinical trials.」
The company continues to establish a framework for the practical application of the immunosuppressive therapy in collaboration with Juntendo University and MEDINET Co.,Ltd. - FY2018-Q2AdvancedAnnual report
「In addition, for the development of a new immunosuppressive treatment using the induction of immune tolerance, which is being jointly researched with Juntendo University, in September 2017 we entered into an outsourcing and contract research agreement with MEDINET Co.,Ltd. to establish a cell-processing platform for commercializing the technology, and are working to establish a framework for the next step, clinical trials.」
For the immunosuppressive therapy using induced immune tolerance, the company moved toward establishing a framework for clinical trials by entering into an outsourcing agreement with MEDINET Co.,Ltd. and beginning technology transfer in September 2017. - FY2017First statedAnnual report
「In February 2017, the company entered into a joint research and development agreement with Juntendo University and began research and development of a new immunosuppressive therapy using induced immune tolerance, which the university had been researching.」
Under the joint research and development agreement with Juntendo University, the company began developing a new immunosuppressive therapy using induced immune tolerance.